Genmab A (GMAB) Receivables - Other (2023 - 2026)

Genmab A has reported Receivables - Other for 4 years, with the latest figure at $968.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other changed N/A year-over-year to $968.0 million; the trailing twelve-month figure through Mar 2026 stood at $968.0 million (changed N/A YoY), and the FY2025 full-year result was $62.0 million, up 26.53% from the prior year.
• Receivables - Other for Q1 2026 stood at $968.0 million, down from $1.1 billion in the prior quarter.
• The five-year high for Receivables - Other was $1.1 billion in Q4 2025, with the low at $43.0 million in Q4 2023.
• Historically, Receivables - Other has averaged $543.0 million across 4 years, with a median of $508.5 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Other gained 13.95% — and 2025, when it soared 2169.39%.
• Genmab A's Receivables - Other stood at $43.0 million in 2023, then grew by 13.95% to $49.0 million in 2024, then soared by 2169.39% to $1.1 billion in 2025, then declined by 12.95% to $968.0 million in 2026.
• The last three Receivables - Other figures came in at $968.0 million (Q1 2026), $1.1 billion (Q4 2025), and $49.0 million (Q4 2024), per Business Quant data.